NCT02125734 - Lung Function and Patient Preference With QVA149 vs. Tiotropium in COPD Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions

Chronic Obstructive Pulmonary DiseaseCOPD

Interventions

DRUG

QVA149

QVA149 capsules 110/50 µg for inhalation via Concep-1-inhaler device, taken once a day

DRUG

Tiotropium

Tiotropium 18 µg capsules for inhalation via HandiHaler device taken once a day

Trial Locations (18)

12203

Novartis Investigative Site, Berlin

13057

Novartis Investigative Site, Berlin

30173

Novartis Investigative Site, Hanover

34121

Novartis Investigative Site, Kassel

42665

Novartis Investigative Site, Solingen

48147

Novartis Investigative Site, Münster

48231

Novartis Investigative Site, Warendorf

48431

Novartis Investigative Site, Rheine

49477

Novartis Investigative Site, Ibbenbüren

53119

Novartis Investigative Site, Bonn

57072

Novartis Investigative Site, Siegen

60318

Novartis Investigative Site, Frankfurt

60389

Novartis Investigative Site, Frankfurt

63263

Novartis Investigative Site, Neu-Isenburg

80686

Novartis Investigative Site, München

82467

Novartis Investigative Site, Garmisch-Partenkirchen

96515

Novartis Investigative Site, Sonneberg

04275

Novartis Investigative Site, Leipzig